Depo-Provera Daubert Ruling: What the Rule 702 Hearing Decides

Last Updated: July 16, 2026 | Reviewed by: Legal Lawsuit Editorial Team | Key Sources: U.S. District Court (N.D. Florida) MDL docket and PubMed/NIH.

Depo-Provera Daubert Ruling: What the July 27, 2026 Rule 702 Hearing Will Decide

Last updated: July 7, 2026

In This Article

1. Rule 702 explained — and the reason for the new July 27 date
2. Why the causation ruling still counts after a settlement
3. Research behind the meningioma claims
4. The vacated Toney v. Pfizer bellwether
5. Next steps once the hearing is over
6. Should you file before the judge rules?
7. FAQ

Rule 702 in the Depo-Provera MDL: What It Is and Why the Date Changed

A Rule 702 hearing is a “gatekeeping” step in which a judge decides, before any trial, whether expert witnesses may testify to a jury at all. In the Depo-Provera MDL, Judge Rodgers first set the hearing for June 24–25, 2026, to assess whether plaintiffs’ general-causation experts could testify that Depo-Provera is capable of causing intracranial meningioma.

Under the court’s June 15 order, the hearing moved to July 27, 2026, in Pensacola, Florida, giving the parties time to finalize the global settlement announced that day. The court said it still expects to decide the Rule 702 motions “in the ordinary course,” because the settlement won’t cover every pending case.

Why the Daubert Ruling Still Matters Despite the Settlement

A settlement in progress doesn’t end the litigation. Judge Rodgers expressly noted that the global agreement, once final, “will not resolve all cases in the MDL,” since only plaintiffs who meet still-undetermined eligibility criteria will be able to join. For everyone else — including many of the more than 5,800 plaintiffs pending in the federal MDL as of July 2026, and women with claims in New York and Delaware state courts, where the settlement isn’t expected to apply — the July 27 causation decision will determine whether their cases can advance toward trial.

According to the June 15 order, plaintiffs who didn’t separately seek leave to offer their own general-causation experts or additional briefing will be bound by the outcome of the July 27 hearing.

The Research Driving the Depo-Provera Lawsuits

The lawsuits stem from a nationwide case-control study published in The BMJ in March 2024 that looked at progestogen use in more than 108,000 French women. Women who used injectable medroxyprogesterone acetate — Depo-Provera’s active ingredient — had 5.55 times the odds of an intracranial meningioma compared with non-users, with the association driven mostly by use lasting a year or longer.

That general-causation science is exactly what the July 27 hearing will weigh — not whether Depo-Provera caused any particular woman’s tumor, but whether the science is reliable enough for experts to testify about it at trial in the first place.

Toney v. Pfizer: The Vacated Bellwether Case

Toney v. Pfizer Inc. was one of the lead cases on track for the MDL’s first bellwether trial, then scheduled for December 7, 2026. Once the June 15 settlement was announced, Judge Rodgers wiped out every trial and pretrial deadline in that case, so it no longer needed to go first as a test trial.

Bellwether trials aren’t permanently off the table, though. Pretrial Order No. 30A, issued that same day, confirms the global agreement won’t resolve every case, so more test trials remain possible for claims outside the settlement’s eligibility criteria once they’re set.

What Comes After the July 27 Hearing

MDL No. 3140 now runs on two parallel tracks. On one, Pfizer and plaintiffs’ leadership are finalizing settlement terms — eligibility rules and payment amounts included, none of which had been made public at the time of writing. On the other, the court keeps the litigation moving for cases the settlement won’t cover, beginning with the July 27 causation decision.

Monthly case management conferences are on the calendar for the rest of 2026, where the court will take up how the settlement applies across the MDL and how non-settling cases will proceed toward trial.

While both tracks unfold, check Legal Lawsuit’s mass tort and active lawsuit tracker for news on other pending litigation.

Should You Act Before the Daubert Ruling?

Attorneys are generally still taking new Depo-Provera cases while both the settlement and the Rule 702 decision are pending. Since settlement eligibility hasn’t been finalized, and state-court cases in places like New York and Delaware likely won’t be covered by the federal deal, waiting for clarity can cost valuable time against your filing deadline. If you received two or more Depo-Provera (or Depo-SubQ Provera 104) shots and were later diagnosed with an intracranial or spinal meningioma, you can get an estimate of your claim’s value or check whether you may qualify based on how claims in this litigation have been assessed so far.

Depo-Provera Daubert Ruling FAQs

1. In plain terms, what does the Rule 702 hearing decide?
It’s the proceeding where Judge M. Casey Rodgers will decide whether plaintiffs’ experts may testify that Depo-Provera can cause intracranial meningioma. The decision applies across MDL No. 3140 and controls whether that scientific evidence can be used at trial in cases the settlement doesn’t resolve.

2. Why did the Depo-Provera Daubert hearing move to July 27, 2026?
Originally scheduled for June 24–25, 2026, it was postponed after Pfizer and plaintiffs’ leadership announced a global settlement in principle on June 15, 2026, to allow time to finalize the terms.

3. Is the litigation over now that there’s a settlement?
No. According to the June 15 order, some MDL cases will remain unresolved by the settlement. Anyone who fails the final eligibility test — plus most plaintiffs suing in New York and Delaware state courts — will still be affected by decisions such as the July 27 Rule 702 ruling.

4. What became of the first Depo-Provera bellwether trial?
Judge Rodgers vacated the trial and pretrial deadlines in Toney v. Pfizer Inc., the first scheduled bellwether, on June 15, 2026, after the settlement announcement, removing the immediate need for the December 7, 2026 trial.

5. Can I still file while the settlement and Daubert ruling are pending?
Yes. Attorneys are generally still accepting cases from women diagnosed with a meningioma after Depo-Provera use. Because settlement eligibility isn’t final, a case review can clarify your options based on your diagnosis and history of use.

Related Posts

• What the 2026 Depo-Provera Global Settlement Means for Claimants
• Background: The Original June 2026 Depo-Provera Daubert Hearing
• Depo Provera Brain Tumor Lawsuit 2026: Who Qualifies

Court and research references: Northern District of Florida MDL No. 3140 page and the 2024 BMJ meningioma study on PubMed.